|Address:||The Jenner Institute, Old Road Campus Research Building Roosevelt Drive, Oxford, OX3 7DQ|
|Tel:||+44 (0)1865 617637|
|Principal areas of research:||Prostate cancer vaccines|
I studied biology at Università degli studi Roma TRE and obtained my PhD at the University of Duisburg-Essen in the summer of 2013. My PhD thesis focused on the reduction of normal tissue damage and improvement of radiation therapy efficacy through the study of specific immunoregulatory molecules and inflammatory cells.
With my main scientific interests being cancer and immunology, I wished to continue research on a project that could directly translate research in a clinical setting. Thus, I joined the prostate cancer vaccine program at the Jenner Institute in September 2013.
Despite the significant advances in the field of immunotherapy as an alternative, or combination treatment of cancer patients, benefits of vaccination still remain low. With the main focus on prostate tumour immunology and immunotherapy, my work at the Jenner Institute includes comparative immunogenicity and efficacy assessments of a range of cancer antigens in pre-clinical mouse models of prostate cancer using viral vectored vaccines and checkpoint inhibitors. The aim of these pre-clinical studies is not only to assess tumour protection targeting well-known prostate cancer antigens, but also to identify new tumour specific antigens and validate them as targets for an effective prostate cancer vaccine for further clinical development.
In the last few years, we have been working on a phase I clinical trial in low-intermediate risk prostate cancer patients receiving heterologous vaccination, now closed. Currently, we are running a phase I/II clinical trial that combines the heterologous vaccination with checkpoint inhibitors in a similar cohort of patients and in metastatic prostate cancer patients.
Cappuccini F, Stribbling S, Pollock E, Hill AV, Redchenko I. Immunogenicity and efficacy of the novel cancer vaccine based on simian adenovirus and MVA vectors alone and in combination with PD-1 mAb in a mouse model of prostate cancer. Cancer Immunol Immunother. 2016 Jun;65(6):701-13.
Cappuccini F, Pollock E, Stribbling S, Hill AVS, Redchenko I. 5T4 oncofoetal glycoprotein: an old target for a novel prostate cancer immunotherapy. Oncotarget. 2017 Jul 18;8(29):47474-89.